Niek F. Casteleijn

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Folkert W. Visser, R. Aerts et al. · JAMA · 2018 · 107 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

R. Aerts, Wietske Kievit, Hedwig M. A. D‘Agnolo et al. · Gastroenterology · 2019 · 83 citations · Full text

Medicine, Genetics, Internal Medicine +12

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Joost P.H. Drenth, Hedwig M. A. D‘Agnolo et al. · American Journal of Kidney Diseases · 2013 · 70 citations · Full text

Medicine, Nephrology, Pharmacotherapy +9

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression

A. Lianne Messchendorp, Esther Meijer, Wendy E. Boertien et al. · Kidney International Reports · 2017 · 49 citations · Full text

Medicine, Clinical Sciences, Nephrology +17

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

Niek F. Casteleijn, Jaime D. Blais, Arlene B. Chapman et al. · American Journal of Kidney Diseases · 2016 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12